UNSPSC 51401536: Metaclazepam

This classification denotes a benzodiazepine with the molecular formula C18H18BrClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2N2B1303L, chemically known as 7-bromo-5-(o-chlorophenyl)-2,3-dihydro-2-(methoxymethyl)-1-methyl-1h-1,4-benzodiazepine but generally known as metaclazepam, which bears US NIH Compound Identifier 71272. European Medicines Agency schedules Metaclazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08800MIG.

UNSPSC 51401536 Metaclazepam is a Commodity code with minimal recent state and local procurement activity under its nominal scope. The single recent opportunity directly tagged to this code — Seminole County's naloxone and drug deactivation systems procurement — involves opioid-reversal medications and harm-reduction equipment rather than metaclazepam, a benzodiazepine derivative no longer in routine clinical use. State and local purchasing under this code does not reflect active procurement of the drug itself but rather related public-health supplies supporting overdose response and community health initiatives. The mix of issuing bodies pursuing pharmaceutical-adjacent procurement spans county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. When state and local procurement activities touch this therapeutic class or pharmaceutical supply chain, they typically originate from county public health agencies and state health commissions managing emergency preparedness, substance abuse treatment, and pharmacy benefit programs.

The geographic spread of recent activity centers on Florida and the Upper Midwest. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. No active procurement of metaclazepam specifically appears in recent state and local solicitations; current activity in this space is dominated by opioid-response medications, generic pharmaceutical supply chains, and pharmacy benefit innovation.